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For patients with advanced malignant melanoma, the 5 y survival rate with current treatment modalities is low.
There is an urgent need for more effective therapeutic concepts. One approach with great potential is to stimulate
the body’s own immune defense to reject cancer cells using CpG oligonucleotides. Distinct oligonucleotides
containing nonmethylated cytidine residues in cytidine-guanosine dinucleotides with particular ﬂanking bases
(CpG motifs) are capable of eliciting powerful immune stimulation by mimicking infectious disease. We evaluated
the in vivo antitumoral effects of CpG oligonucleotides against human malignant melanoma xenografts in NOD/
SCID mice. CpG oligonucleotides administered in single peritumoral subcutaneous injections three times per week
resulted in elevated plasma levels of interleukin-12 and signiﬁcant inhibition of the growth of established tumor
xenografts by 60% (po0.016) compared to the saline control. In addition to this a signiﬁcant invasion of
macrophages into tumor xenografts and increased numbers of Langerhans-cell-derived dendritic cells in draining
lymph nodes could be observed. Our ﬁndings demonstrate the antitumor activity of oligonucleotides containing
immune-stimulatory CpG motifs in a xenotransplantation model with absent B, T cells and a lack of natural killer
cell function.
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The incidence of malignant melanoma shows a clear
increase over the last decades. The risk of getting a
melanoma was 1:1500 in 1935, but in 1991 it was already
1:105 in the USA and Europe and it is currently estimated to
be less than 1:75 in Caucasian individuals (Stadelmann et
al, 1998). For melanoma, the only therapeutic option with
curative potential is the early and complete excision of the
primary lesion. In advanced disease, the 5 y survival rate
drops dramatically (Dreiling et al, 1996).
The success of current concepts of chemotherapy for
this patient group is limited. The most effective single agent
therapy is still dacarbazine with a response rate of 20%–
30% (Chapman et al, 1999). Recent evidence suggests that
combination treatment strategies like the Dartmouth regi-
men (dacarbazine, cisplatin, carmustine, and tamoxifen) are
not superior to single agent dacarbazine therapy (Chapman
et al, 1999). The need for new and improved treatment
modalities is obvious.
Over the last years numerous innovative therapeutic
concepts have been investigated, which contributed to a
better understanding of the biology of this malignant
disease. One of these approaches is to stimulate the host’s
own immune defense to reject cancer cells.
In mammalian DNA, most cytidine-guanosine dinucleo-
tides (CpG) are methylated and their frequency is low due to
a higher mutation rate of 5-methylcytosine to tymidine (Bird,
1980). This is in contrast to bacterial DNA, where
unmethylated CpG dinucleotides occur at a frequency
expected by random distribution. Based on this difference,
bacterial DNA can be detected by the vertebrate immune
system.
Short DNA fragments containing at least one unmethy-
lated CpG base pair and certain flanking bases are required
for immune activation. Synthetic CpG oligonucleotides with
these characteristics were first described for mice in 1995
by Krieg et al. They showed that CpG oligodeoxynucleo-
tides (ODN) alone are not toxic to cancer cells but can
activate murine splenocytes to lyze tumor cells ex vivo.
Later, immune-stimulatory CpG ODN sequences with high
activity in the human immune system were identified
(Hartmann et al, 1999).
The underlying hypothesis of CpG ODN function is that
subcutaneously injected CpG ODN are taken up by
dendritic cells (DC) into endosomes (Manzel and Macfar-
lane, 1999) and activate and mature DC (Jakob et al, 1998;
Sparwasser et al, 1998; Hartmann et al, 1999) via the
intracellular TLR9 receptor of the highly conserved toll-like
receptor family (Hemmi et al, 2000), MyD88 (Schnare et al,
Abbreviations: CpG, cytidine-phosphate-guanosine dinucleotide;
DC, dendritic cell; NK cell, natural killer cell; NOD, non-obese
diabetes; ODN, oligodeoxynucleotides; SCID, severe combined
immunodeficiency.
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2000), and the MAP kinase pathway (Hacker et al, 1999).
The exact mechanism is not yet fully elucidated, however.
In severe combined immunodeficiency (SCID) mice,
natural killer (NK) cells were described as the main effector
cells of CpG-mediated immune activation (Ballas et al,
1996). Recently the effectiveness of CpG ODN 1585 in a
murine melanoma SCID mouse model was reported (Ballas
et al, 2001), showing that CpG ODN prolong survival of
SCID mice challenged intraperitoneally with murine mela-
noma cells. SCID mice lack functional Tand B cells but have
normal DC and NK cell function. The observation that
depletion of NK cells abrogated the antitumor effect
supported a key role of NK cells in this model.
In the NOD/SCID mouse, the SCID mutation has been
transferred from the C.B-17 congenic strain background of
SCID mice onto the diabetes susceptible NOD background.
NOD/SCID mice lack functional lymphoid cells and show
little or no serum immunoglobulins. In contrast to SCID
mice, however, NK cell activity in NOD/SCID mice is
markedly reduced due to the NOD background (Shultz et
al, 1995). Furthermore Shultz et al even demonstrated that
chronic treatment of NOD/SCID mice with anti-NK1.1
antibody does not significantly further depress NK cell
activity in these mice (Shultz et al, 1995).
Here we investigate the in vivo immune-stimulatory and
antitumoral potential of CpG ODN in a NOD/SCID xeno-
transplantation model. The CpG ODN 1585 used is known
to be highly active to increase the activity of the innate
immune system of mice (Ballas et al, 2001).
We demonstrate antitumor activity of CpG ODN against
human melanoma xenotransplants in NOD/SCID mice. This
effect is associated with activation of DC and a sustained
increase of interleukin-12 (IL-12). Our data provide evidence
that, in the absence of T cells and B cells, innate effector
cells other than NK cells may play a major role in the
antitumor activity of CpG ODN.
Results
CpG ODN inhibit tumor growth Treatment with CpG ODN
1585 over a course of 4 wk resulted in significant antitumor
effects: CpG ODN inhibited the growth of established
human melanoma xenografts in NOD/SCID mice by 60%
compared to the saline control (Fig 1). This difference was
highly significant with a p value of less than 0.016.
DC migrate to lymph nodes It has been shown by Ban
et al (2000) that CpG ODN activate DC migration. Therefore,
we immunostained draining lymph nodes with CD205
monoclonal antibodies after 1 wk of treatment. CD205
(DEC-205) is a surface receptor of DC involved in antigen
processing (Jiang et al, 1995; Swiggard et al, 1995).
Compared to draining lymph nodes of saline-treated
animals (Fig 2a), we found high numbers of CD205 positive
cells in lymph nodes of CpG-ODN-stimulated mice (Fig 2b).
To further characterize these DC we performed anti-
mLangerin staining specific for Langerhans cells of the skin
and Langerhans-cell-derived DC (Valladeau et al, 2002). We
observed a marked increase of Langerhans-cell-derived DC
in lymph nodes of CpG-ODN-stimulated mice (Fig 2d)
compared with unstimulated mice (Fig 2c).
IL-12 elevation in peripheral blood Murine DC have been
shown in vitro to be the primary IL-12-producing cell
population following CpG ODN stimulation (Jakob et al,
1999). We therefore measured IL-12 plasma levels after 1
wk and 4 wk of treatment. In accordance with the observed
activation of DC in the lymph nodes of CpG-ODN-treated
animals, we found a sustained elevation of total IL-12 levels
in the peripheral blood of CpG-ODN-treated animals
compared to saline-treated animals. After 1 wk of treatment
IL-12 levels were elevated by 40% (po0.049) (Fig 3a) and
after 4 wk IL-12 levels were elevated by 55% (pooled
samples) compared to the saline control (Fig 3b). This
finding is in contrast to observations made after lipopoly-
saccharide exposure where DC produced IL-12 only
transiently and became refractory to further stimulation
(Langenkamp et al, 2000).
Macrophage inﬁltration in tumors The F4/80 antigen is a
surface marker suitable for detecting mature mouse
macrophages. Comparing numbers of macrophages in
melanoma xenotransplants of saline-treated animals (Fig
4a) and CpG-ODN-treated animals (Fig 4b), we observed a
marked increase of macrophages in the CpG ODN group
characterized by increased numbers of F4/80 positive cells
in immunostaining of tumor tissue.
DC inﬁltration of tumors There was no major DC infiltra-
tion of tumors in CpG-ODN- or saline-treated animals (data
not shown).
Discussion
It has been demonstrated before that CpG ODN are
capable of eliciting an antitumor response in SCID mouse
model systems lacking functional B or T cells. The exact
mechanism by which CpG ODN achieve this antitumor
response is not known. It has been suggested that NK cells
are mainly responsible for this effect. In support of this
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Figure1
Growth of human melanoma xenotransplants in NOD/SCID mice.
Therapy with CpG ODN or saline solution was started on day 5 after
tumor inoculation, with subcutaneous injections three times a week
until day 33. Mean  SD, n¼ 6.
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hypothesis Ballas et al (2001) have shown that depletion of
NK cells abrogates the CpG ODN antitumor effect in a
murine melanoma SCID mouse model.
In our study we used a NOD/SCID mouse model,
deficient in NK cell as well as B and T cell function.
Interestingly, even in this system with an only rudimentary
immune system, CpG ODN significantly inhibited growth of
human melanoma xenotransplants.
We examined the draining lymph nodes by immunohis-
tochemistry in an attempt to further elucidate the cell types
involved in this antitumor effect. We observed a dramatic
increase in the number of DEC-205þDC in CpG-treated
animals compared with control animals. Further character-
ization of these DC indicates that the majority are
Langerhans-cell-derived DC as determined by mLangerin
staining. It is tempting to speculate that these Langerhans
cells have been stimulated by CpG ODN to migrate out of
the skin into the lymph nodes. A simultaneous elevation in
IL-12 levels in the serum might be attributed to activated
Langerhans-cell-derived DC. It is unclear whether the
elevation of IL-12 is involved in the inhibition of tumor
growth observed, as the CpG antitumor effect in IL-12
knockout mice bearing syngenic melanoma does not differ
from that in wild-type mice (Ballas et al, 2001).
In contrast to the observed activation of Langerhans cells
in our murine model, Krug et al (2001) showed that, in
humans, plasmacytoid DC are the only subgroup of DC
expressing TLR9, which is needed for recognition of CpG
ODN. They also showed that the CpG ODN 1585, used in
our study, seems to be a potent inducer of type I interferons
and IL-12 (Krug et al, 2001). Similarly, we observed an
elevation of IL-12 in our model, but we could not detect a
possible elevation of type I interferons with the commercial
type I interferon ELISA kits available. Due to the species
restriction of interferons, however, a direct antiproliferative
effect of type I interferons seems improbable in a xeno-
transplantation model.
One possible type I interferon effect in our model could
be activation of macrophages. The role of activated
macrophages in tumor immunity is a widely studied field
(Klimp et al, 2002), and indeed, we observed a major
infiltration of F4/80 positive macrophages into tumor
xenotransplants.
Figure 2
Immunohistology of draining lymph
nodes. (a), (b) stained with CD205
(DEC-205, Ly-75) for DC (a) of CpG-
ODN-treated animals and (b) of saline-
treated animals; (c), (d) stained using
mLangerin antibodies for Langerhans-
cell-derived DC (c) of CpG-ODN-treated
animals and (d) of saline-treated ani-
mals. Scale bars: 50 mm.
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Figure 3
Peripheral blood serum levels of IL-12. (a) after 1 wk of treatment,
mean  SD, n¼3; (b) after 4 wk of treatment, pooled samples, n¼ 6.
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Recently there have been questions as to whether the
antitumoral effect of antisense ODN can, at least in part, be
attributed to immune-stimulatory effects of CpG motifs.
Antisense ODN specifically inhibit gene expression by
binding to complementary mRNA and may incidentally
contain CpG motifs (Jansen et al, 1998). There have been
attempts to investigate the antitumoral potential of anti-
sense ODN in model systems excluding B, T, and NK cell
mediated immune effects (Klasa et al, 2000). Indeed Ballas
et al (2001) have shown that depletion of NK cells in SCID
mice abrogated an antitumoral effect of CpG ODN. As in our
study CpG ODN had an antitumor effect, the use of NOD/
SCID xenotransplantation models is inappropriate when
trying to exclude antitumor effects mediated by immune-
stimulatory CpG motifs in antisense oligonucleotides.
In conclusion, we observed a significant antitumor effect
by CpG ODN with activation of Langerhans-cell-derived DC
and macrophages warranting further studies on CpG
oligonucleotides as a novel approach for treating human
melanoma.
Materials and Methods
518A2 human melanoma cells The cells were maintained in
basal tissue culture medium (Gibco BRL, Paisley, UK) supplemen-
ted with 10% fetal bovine serum and 1% antibiotics in a humidified
5% CO2, 95% ambient air atmosphere at 371C.
CpG ODN 1585 CpG ODN 1585 was kindly provided by Coley
Pharmaceutical Group (Wellesley, MA). The sequence of CpG ODN
1585 is GGGGTCAACGTTGAGGGGGG, with a mixed backbone of
phosphorothioate linkages between the first two bases at the 50
end and the last five bases at the 30 end and the remaining central
bases carrying phosphodiester linkages.
Human melanoma NOD/SCID xenotransplantation model
Pathogen-free female NOD/SCID mice were obtained from M&B,
Ry, Denmark. Animals were housed in microisolator cages in
laminar flow racks and received autoclaved food and water ad
libitum. 1.5  107 518A2 human melanoma cells resuspended in
200 mL phosphate-buffered saline (PBS) were injected subcuta-
neously into the left lower flank of NOD/SCID mice. When mice had
developed palpable subcutaneous tumors they were randomized
into two groups. One group (n¼ 6) received 100 mg CpG ODN 1585
in a volume of 200 mL three times a week and the second group
(n¼ 6) received saline solution 200 mL three times a week.
Treatment was administered by single subcutaneous injections in
the direct vicinity of the tumors. Tumor size was assessed twice
weekly by caliper measurement. After 4 wk of treatment blood was
collected and mice were sacrificed.
In a second experiment (n¼ 3) with the same setup, mice were
sacrificed after 1 wk of treatment. Blood was collected and
peritumoral skin, tumor tissue, and draining lymph nodes were
embedded in Tissue-Tec II (Miles, Elkhart, IN) and frozen in liquid
nitrogen. The study was approved by the University of Vienna
Animal Welfare Committee.
Immunohistology CD205 antibodies Cryostat sections (5 mm) of
tumor tissue and lymph nodes were subjected to immunostaining.
Unfixed sections were blocked 10 min and incubated overnight at
41C with the CD205 concentrated supernatant antibodies (Serotec,
Oxford, UK) diluted 1:2 in PBS. Following washing with Dulbecco’s
Phosphate Buffered Saline-Tween 20 (BioRad, Munich, Germany)
(DPBS-T), antibody binding was visualized by further incubation
with biotinylated goat antirat secondary antibody (Amersham
Biosciences Europe Bucks, UK) diluted 1:200 for 1 h at 211C and
subsequently with Texas-Red-labeled streptavidin (Amersham
Biosciences Europe) diluted 1:100 for 45 min at 211C. After further
washing with DPBS-T, sections were covered in Fluoroprep and
photographed immediately.
mLangerin antibodies Cryostat sections (5 mm) of lymph nodes
were subjected to immunostaining. Unfixed sections were blocked
30 min and incubated overnight at 41C with mLangerin antibodies
(Valladeau et al, 2002) (clone 929F3, courtesy of Sem Saeland,
Schering-Plough, Dardilly, France) diluted 1:500 in PBS. Following
washing with DPBS-T, antibody binding was visualized by further
incubation with biotinylated goat antirat secondary antibody
(Amersham Biosciences Europe) diluted 1:200 for 1 h at 211C.
After washing with DPBS-T slides were incubated for 30 min with
the ABComplex/HRP Kit (DAKO, code no. K0377 Copenhagen,
Denmark). Following a further washing step the DAB-chromogen
solution was incubated until a visible color reaction was observed.
Slides were washed, counterstained with Mayer’s hematoxylin,
and mounted with Aquatex (Merck, code no. 1.08562 Darmstadt,
Germany).
F4/80 antibodies Cryostat sections (5 mm) of tumor tissue were
subjected to immunostaining. Unfixed sections were blocked 30
min and incubated overnight at 41C with F4/80 antibodies (clone
A3-1, Serotec) diluted 1:20 in PBS. Further steps were performed
as described above.
ELISA ELISA for quantitative measurement of total IL-12 in mouse
serum was performed according to the manufacturer’s instructions
(Amersham Pharmacia, Piscataway, NJ). In brief, biotinylated
antibody reagent was added to duplicate specimens of mouse
serum diluted 1:2 in standard diluent and incubated for 1 h. The
Figure4
Microphage infiltration in tumors.
Tumor tissue after 1 wk of treatment,
stained with F480 antibody for macro-
phages: (a) saline treated (b) CpG ODN
treated. Scale bar: 50 mm.
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plate was washed, and after 1 h incubation with streptavidin
horseradish peroxidase solution, premixed tetramethyl benzidine
(TMB) substrate solution reagent was added to each well and
incubated at room temperature for 30 min. Prior to determination of
optical density at 450 nm stop solution was added. Serum
concentrations were calculated using a standard curve.
Statistical signiﬁcance The statistical significance of differences
in tumor volume among treatment groups was calculated by using
the Mann–Whitney U test (Statistica 5.1, StatSoft, Tulsa, OK). p
values of 0.05 were considered to be of statistical significance.
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